⚕️CPT 67228 - Panretinal Photocoagulation (PRP)

Overview

CPT code 67228 describes panretinal photocoagulation (PRP), a laser-based ablative procedure used to treat extensive or progressive retinopathy. The procedure involves selective destruction of the peripheral, ischemic retina using thermal laser energy. By eliminating poorly perfused retinal tissue that produces excessive vascular endothelial growth factor (VEGF), PRP dramatically reduces the stimulus for abnormal neovascularization and stabilizes or causes regression of proliferative disease.

Historical Context and 2016 Paradigm Shift

Prior to January 1, 2016, CPT 67228 carried a 90-day global period and included language permitting treatment across multiple sessions within that 90-day window under a single code. This approach reflected a clinical reality: panretinal photocoagulation causes significant inflammation, pain, and risk of transient macular edema if performed in a single marathon session. Providers routinely staged treatment into 2-4 separate sessions to optimize safety and patient tolerance.

2016 CMS Decision: The Centers for Medicare & Medicaid Services fundamentally restructured this code, reducing the global period from 90 days to 10 days^{CMS PFS Final Rule 2015}. This change reflected a philosophical shift: each distinct treatment session now constitutes a billable event. The reimbursement per session decreased to reflect this change, but the total potential revenue across multiple staged sessions can exceed the old single 90-day payment. This restructuring incentivizes transparency and accurate episode documentation but created billing complexity that practitioners must navigate carefully.

Clinical Indications & Disease States

Proliferative Diabetic Retinopathy (PDR)

The most common indication. Characterized by neovascularization of the optic disc (NVD), neovascularization elsewhere (NVE), or extensive intraretinal microvascular abnormalities (IRMA). Untreated PDR carries a 50% risk of severe vision loss within 5 years. PRP reduces this risk to <5% in properly treated eyes.

Why it works: Ischemic retina produces VEGF proportional to the degree of hypoxia. Ablating ischemic peripheral retina eliminates this VEGF source, allowing existing neovascularization to regress and preventing new vessel proliferation.

Severe Non-Proliferative Diabetic Retinopathy (NPDR)

Eyes approaching the PDR threshold. Characteristics include:

4-point intraretinal hemorrhages in ≥2 quadrants
Venous beading in ≥2 quadrants
Prominent IRMA in ≥1 quadrant
No neovascularization present yet

ETDRS Landmark: The Early Treatment Diabetic Retinopathy Study (ETDRS) established that eyes with “high-risk characteristics” benefit from prophylactic PRP even without overt neovascularization. This remains the standard of care and justifies 67228 coding in severe NPDR cases.

Central Retinal Vein Occlusion (CRVO) with Ischemia

CRVO complicated by extensive capillary nonperfusion and secondary neovascularization (rubeosis iridis, neovascular glaucoma). PRP is indicated when ischemic area exceeds ~30% of retinal surface.

Branch Retinal Vein Occlusion (BRVO) with Extensive Ischemia

Localized venous obstruction causing quadrantic or sectoral ischemia with neovascularization. PRP may be applied selectively to the ischemic sector.

Ocular Ischemic Syndrome (OIS)

Severe carotid artery stenosis or occlusion resulting in global ocular ischemia, retinal whitening, dot-blot hemorrhages, and neovascularization. PRP is often performed in conjunction with systemic vascular intervention.

Retinopathy of Prematurity (ROP) - Use 67229 Instead

Important Distinction: Premature infants with progressive ROP are treated with 67229 (Treatment of extensive or progressive retinopathy, preterm infant), not 67228. This reflects different pathophysiology and treatment algorithms specific to the developing retina in preterm neonates.

Work RVU and Reimbursement Architecture

Work RVU Composition

wRVU: 3.80-4.10^{CMS MPFS 2026}

This range reflects:

Physician Work Time: Approximately 20-30 minutes intraservice time (marking, positioning, photocoagulation application, slit-lamp examination)
Technical Skill: High—requires precise beam positioning, power calibration, burn pattern placement
Judgment/Decision-Making: Moderate—assessing adequacy of retinal ablation in real-time; deciding when treatment is complete or requires additional sessions
Psychological Stress: Low—non-incisional, low systemic risk, but patient discomfort is significant

Practice Expense and Facility Differential

One of the most significant changes following the 2016 restructuring involves how CMS allocates practice expense between office-based and facility-based settings.

Non-Facility (Office, POS 11):

Providers bear full depreciation, maintenance, and calibration costs for expensive laser equipment ( $75, 000 -$ 250,000+ for argon/diode systems)
Higher PE RVU (~8-9 units)
Total RVU: ~11-13 units
Medicare allowable (2026, varies by GPCI): Approximately $365 -$ 435

Facility (ASC/Hospital, POS 24/22):

Facility owns/maintains equipment; provider’s practice expense is minimal
Lower PE RVU (~3-4 units)
Total RVU: ~7-8 units
Medicare allowable (2026): Approximately $235 -$ 285

Impact: Office-based retinal practices have ~55% higher reimbursement per session compared to ASC-based practices—a significant factor in practice economics and location decisions^{CMS Practice Expense Methodology Update}.

Conversion Factors (2026 Estimates)

Using estimated 2026 CMS conversion factor of $33.58 per RVU for non-qualifying APM participants:

Non-facility 67228: 11.5 RVU × $33.58 = * *$ 386**
Facility 67228: 7.8 RVU × $33.58 = * *$ 262**

These are baseline Medicare rates; commercial payers typically reimburse 120-200% of Medicare, and managed Medicaid varies widely by state.

Global Period: The 10-Day Architecture

Global Days: 010

This is a critical operational detail that fundamentally changed how retina practices bill and manage care.

What IS Included (Days 0-10)

Preoperative E/M (same day, unless billed with modifier 25)
The laser photocoagulation application itself
Topical anesthesia or retrobulbar block administered by the surgeon
Routine postoperative follow-up in the office (visual acuity check, slit-lamp examination, IOP assessment)
Management of expected side effects (postoperative inflammation, mild vision fluctuation)

What IS NOT Included (Separately Billable)

Postoperative E/M after Day 10: If a patient returns on Day 11 or later for follow-up and requires comprehensive evaluation addressing new or related concerns, an E/M can be billed with modifier 79 (unrelated procedure during postoperative period)
Diagnostic testing within the global period: 92235 (Fluorescein angiography), 92234 (OCT), 92250 (Fundus photographs)—these are separate procedures with their own RVU value and are always separately billable
Concurrent focal laser on same eye: Complex bundling rules apply (see NCCI section below)
Contralateral eye treatment within 10 days: Use modifier 79-LT or 79-RT to break the bundle

Practical Staging Scenario

Day 1 (Session 1): 1,500 laser burns to right eye, extensive peripheral ablation

Bill 67228-RT
Global period starts (Days 1-10)
Patient follows up Day 3 (routine postop check, included in global)

Day 15 (Session 2): Complete PRP with additional 1,200 burns to right eye

Bill 67228-RT again (Day 15 is outside the global period)
This session initiates a NEW 10-day global (Days 15-24)
Routine postoperative follow-up on Day 17 included in this new global

Day 8 (within first global period): Patient needs same-day treatment to left eye

Bill 67228-79-LT
Modifier 79 tells payer: “This is unrelated to the right eye’s global period”
Left eye establishes its own 10-day global (Days 8-17)

This structure is fundamentally different from the old 90-day paradigm. Providers must carefully track initiation dates and document medical necessity for each staged session to justify separate billing.

Assistant Surgeon Status

Status: NOT PAYABLE

CPT 67228 carries Status Indicator 0 on Medicare’s Physician Fee Schedule Database, meaning assistant surgeon services are not covered and will be denied^{CMS PFS Database}.

Why This Determination Was Made

Unlike incisional surgery where a second surgeon actively assists with hemostasis, retraction, and tissue handling, laser photocoagulation is inherently a solo procedure:

The surgeon sits at the slit lamp with both hands free (one operating the laser joystick/controls, one operating the slit lamp focus/positioning)
An assistant cannot meaningfully participate in the core therapeutic work—the laser beam is generated by the device, not manipulated by human hands in the traditional sense
Topical anesthesia eliminates the need for anesthesia personnel involvement
Patient positioning and cooperation are more critical than surgical assistance

Billing Implications

Appending modifiers 80 (Assistant Surgeon), 81 (Minimum Assistant), 82 (Qualified Surgeon Not Available), or AS (Physician Assistant/NP as Assistant) will result in:

Automatic denial without requiring appeal
No medical review—the denial is coding-based
Potential overpayment recovery if billed retrospectively

Exception Caveat: If an assistant is utilized for anesthesia administration (retrobulbar block) or periocular preparation, that service is billed under anesthesia codes, not as an assistant to the primary CPT code.

Includes

When billing 67228, the following services are bundled and cannot be billed separately on the same date of service:

Procedural Includes

✓ Topical anesthesia application: Tetracaine, proparacaine, or combination drops used to numb the ocular surface

✓ Retrobulbar or peribulbar anesthesia (if administered by the operating surgeon): Local infiltration around the orbit to eliminate pain during prolonged slit-lamp work

✓ Slit-lamp positioning and alignment: Including indirect viewing lens use if needed

✓ Laser photocoagulation application: All thermal burns and retinal ablation

✓ Intraoperative monitoring: IOP checks, visual feedback assessment

✓ Routine postoperative examination and follow-up (within 10-day global period): Same-day postop check, follow-up at Day 1-3, postoperative inflammation management

✓ Postoperative pharmacology within the global period: Topical anti-inflammatory drops (prednisolone, dexamethasone)

Documentation Includes

✓ Laser settings documentation: Power, spot size, duration, number of burns applied

✓ Treatment pattern description: Whether panretinal, sector-specific, or combination

✓ Extent of ablation: Percentage of retina treated, areas treated

✓ Patient tolerance and complications: Discomfort level, transient media changes, IOP response

Excludes

The following services are NOT included in 67228 and must be billed separately with appropriate modifiers:

Diagnostic Imaging and Testing

❌ 92235 - Fluorescein angiography (FA)

Often performed preoperatively to assess perfusion status and guide treatment zones
Separately billable even if performed same day
Use no modifier needed (inherently distinct)

❌ 92234 - Optical Coherence Tomography (OCT)

Documents baseline macular thickness before PRP
Separately billable preoperatively or postoperatively
Use no modifier needed

❌ 92250 - Fundus photography (color slides or digital)

Documentation of disease extent
Separately billable
Use no modifier needed

❌ 92260 - Myopia, hyperopia, astigmatism, and presbyopia screening

If refraction needed for accurate documentation

Focal Laser for Macular Edema

❌ 67210 - Destruction of localized lesion of retina, photocoagulation

This is a critical bundling scenario. If a patient has both:

Diabetic macular edema (treated with focal laser to the macula), AND
Proliferative disease (treated with PRP to the periphery)

Both procedures can theoretically be billed together, BUT:

National Correct Coding Initiative (NCCI) edits mark 67228 and 67210 as mutually exclusive on the same eye
The “winner” (primary procedure) in bundling disputes is typically 67228 (the more extensive treatment)
However, if documentation rigorously separates the pathologies (e.g., “Focal laser applied specifically to superior temporal macula for edema, distinct from panretinal ablation for PDR”), modifier 59 (Distinct Procedural Service) or XS (Separate Structure) may allow both codes to be paid
Success of dual coding depends on:
Clear documentation that lesions are distinct anatomical targets
Separate laser settings/parameters for each treatment
Temporal separation (one performed before the other, not simultaneously)
Strong medical justification in the operative note

Safest Approach: If both focal and panretinal treatment are medically indicated same-eye same-day, bill 67228 primarily. Document the focal laser work in detail. Query your payer’s NCCI override policy before submitting. Many payers allow override with proper documentation; others deny the 67210 automatically.

Evaluation and Management Services

❌ E/M codes (99202-99215) can be billed with modifier 25 if:

The E/M service is substantial and separately identifiable
E/M addresses issues distinct from the decision to perform PRP
Example: Patient comes for routine diabetic retinopathy monitoring; physician discovers new PDR and performs PRP same day. The comprehensive exam and decision-making process can be coded separately with 25
Example: Patient returns for unrelated eye complaint (dry eye, presbyopia assessment) and incidentally has PRP performed. The unrelated E/M can be billed.

Without modifier 25: The preoperative work to arrive at the decision for PRP is considered part of the procedure’s inherent work and is bundled into 67228.

❌ Anterior segment lasers (e.g., 65855 Cycloablation, 65860 Trabeculoplasty)

These are distinct anatomical areas and can be billed separately with no modifier needed if performed same day

❌ Intravitreal injections (e.g., 67040 Intraocular injection of medication)

Anti-VEGF injections (bevacizumab, ranibizumab, aflibercept) are sometimes given in conjunction with or instead of PRP
These are separately billable
No modifier needed; inherently distinct

ICD-10-CM Diagnosis Codes & HCC Risk Adjustment

Primary Indications with ICD-10 Codes

Type 1 Diabetes with Proliferative Diabetic Retinopathy (PDR):

E10.3511 - Type 1 diabetes with PDR with macular edema, right eye
E10.3512 - Type 1 diabetes with PDR with macular edema, left eye
E10.3513 - Type 1 diabetes with PDR with macular edema, bilateral
E10.3591 - Type 1 diabetes with PDR without macular edema, right eye
E10.3592 - Type 1 diabetes with PDR without macular edema, left eye
E10.3593 - Type 1 diabetes with PDR without macular edema, bilateral

Type 2 Diabetes with Proliferative Diabetic Retinopathy (PDR):

E11.3511 - Type 2 diabetes with PDR with macular edema, right eye
E11.3512 - Type 2 diabetes with PDR with macular edema, left eye
E11.3513 - Type 2 diabetes with PDR with macular edema, bilateral
E11.3591 - Type 2 diabetes with PDR without macular edema, right eye
E11.3592 - Type 2 diabetes with PDR without macular edema, left eye
E11.3593 - Type 2 diabetes with PDR without macular edema, bilateral

Type 1 Diabetes with Severe Nonproliferative Diabetic Retinopathy (NPDR):

E10.3491 - Type 1 diabetes with severe NPDR without macular edema, right eye
E10.3492 - Type 1 diabetes with severe NPDR without macular edema, left eye
E10.3493 - Type 1 diabetes with severe NPDR without macular edema, bilateral
E10.3411 - Type 1 diabetes with severe NPDR with macular edema, right eye

Type 2 Diabetes with Severe Nonproliferative Diabetic Retinopathy (NPDR):

E11.3491 - Type 2 diabetes with severe NPDR without macular edema, right eye
E11.3492 - Type 2 diabetes with severe NPDR without macular edema, left eye
E11.3493 - Type 2 diabetes with severe NPDR without macular edema, bilateral

Non-Diabetic Retinal Conditions:

H34.90 - Central retinal vein occlusion, unspecified
H34.8110 - Central retinal vein occlusion, right eye, with macular edema
H34.8120 - Central retinal vein occlusion, left eye, with macular edema
H34.8210 - Branch retinal vein occlusion, right eye, with macular edema
H34.8220 - Branch retinal vein occlusion, left eye, with macular edema
H35.051 - Retinal neovascularization, unspecified, right eye
H35.052 - Retinal neovascularization, unspecified, left eye

HCC Risk Adjustment Impact

Hierarchical Condition Categories (HCC) are chronic disease codes that increase risk adjustment factors (RAF scores) for Medicare Advantage and other value-based arrangements. Many retinal conditions trigger significant HCC coding.

ICD-10 Code	HCC Category	RAF Weight (CMS-HCC V28)	Clinical Significance
E10.3591 or E11.3591	HCC 19 (Diabetes with End-Organ Damage) + HCC 122 (Proliferative Diabetic Retinopathy)	~0.60-0.75 combined	High-risk; indicates severe microvascular complication
E10.3511 or E11.3511 (with macular edema)	HCC 19 + HCC 122 + HCC eye component	~0.80-1.00 combined	Vision-threatening; greater risk impact
E10.3491 or E11.3491 (severe NPDR)	HCC 19 only (HCC 122 reserved for overt proliferation)	~0.40-0.50	Moderate risk; indicates disease progression
H34.8110 (CRVO)	HCC dependent on underlying cause

Critical Coding Point for Risk Adjustment:

Accurate laterality coding (E11.3591 unilateral vs. E11.3593 bilateral) directly impacts RAF scores. Bilateral disease carries higher severity weighting. Coders must verify which eye(s) actually received treatment and code accordingly—coding both eyes when only one was treated inflates RAF scores and triggers audit risk.

HCC Capture During Service: When a patient undergoes 67228, the operative note must explicitly document the disease stage (PDR vs. severe NPDR, presence/absence of macular edema) to enable accurate ICD-10 assignment. Vague documentation like “diabetic retinopathy, both eyes” misses HCC capture opportunities and creates compliance risk.

MS-DRG Assignment

67228 is an outpatient-dominant procedure—>99% of cases are billed in office (POS 11) or ambulatory surgery center (POS 24) settings and do not trigger MS-DRG assignment.

Rare Inpatient Scenario

If a patient is admitted to an inpatient hospital setting (e.g., hospitalization for uncontrolled diabetes with acute vision-threatening PDR), and 67228 is performed during that admission:

Relevant MS-DRGs:

DRG 124: Disorders of the eye (except retinitis pigmentosa) with major complications or comorbidities
DRG 125: Disorders of the eye (except retinitis pigmentosa) without major complications or comorbidities
DRG 126: Acute major eye infections

The 67228 procedure itself would be bundled into the DRG payment and not separately billable to the patient. The DRG payment is determined by the principal diagnosis (the retinal condition requiring treatment) plus secondary diagnoses (comorbidities like diabetes complications, hypertension, etc.).

Why This Matters: If a retina practice is approached to provide inpatient laser services, understand that reimbursement flows through the hospital’s DRG, not as a line-item professional fee. Negotiate professional service agreements with the hospital accordingly.

Code Tree: Retinal Destruction Procedures

CPT Code Family (67200-67299 Range)

67200 - 67299: DESTRUCTION OF LESION OF RETINA AND CHOROID │ ├── CRYOTHERAPY / DIATHERMY (Localized) │ ├── 67208: Destruction of localized lesion of retina │ │ (cryotherapy, diathermy) │ └── Typical use: Small tumors, selected vascular lesions │ ├── PHOTOCOAGULATION (Localized) │ ├── 67210: Destruction of localized lesion of retina │ │ (photocoagulation) │ └── Typical use: Focal macular edema, small neovascular lesions │ ├── PHOTOCOAGULATION (Extensive/Progressive) │ ├── 67227: Destruction of extensive or progressive retinopathy │ │ (cryotherapy, diathermy) │ ├── 67228: Treatment of extensive or progressive retinopathy ← YOU ARE HERE │ │ (photocoagulation) │ └── 67229: Treatment of extensive or progressive retinopathy, │ preterm infant (ROP) │ ├── CHOROID DESTRUCTION │ ├── 67220: Destruction of localized lesion of choroid │ │ (photocoagulation) │ └── Typical use: CNV, circumscribed choroidal hemangioma │ └── COMPLEX PROCEDURES ├── 67250: Chorioretinopathy, photodynamic therapy (PDT) ├── 67255: PDT with indocyanine green angiography └── Typical use: Age-related macular degeneration (exudative)

Key Distinctions

Feature	67210	67228
Scope	Localized lesion—discrete, limited area	Extensive/Progressive—widespread disease
Typical Location	Central retina (macula)	Peripheral retina (periphery)
Laser Burn Count	20-100 burns	1,000-3,000+ burns
Operative Time	5-15 minutes	20-45 minutes per session
Anesthesia	Topical usually sufficient	Often requires retrobulbar block for comfort
Indication Examples	Diabetic macular edema; small branch vein occlusion blot; extrafoveal choroidal neovascularization	Proliferative diabetic retinopathy; extensive retinal vein occlusion; ocular ischemic syndrome
Bilateral Potential	Yes, but typically unilateral focus	Often bilateral (both eyes require treatment)
Global Period	010 (10 days)	010 (10 days)

Clinical Pearl: A patient with PDR affecting both eyes will require two separate 67228 codes with appropriate laterality modifiers. A patient with focal macular edema in one eye will receive one 67210 code. A patient with both focal edema and peripheral ischemia may receive both 67210 and 67228 on the same eye, but strict NCCI rules apply.

Modifiers for 67228

Anatomical Laterality Modifiers

RT - Right Eye

Used when PRP applied to right eye only
Example: 67228-RT

LT - Left Eye

Used when PRP applied to left eye only
Example: 67228-LT

50 - Bilateral Procedure

Used when PRP applied to both eyes during same operative session
Reimbursement: Typically 150% of single-eye fee (check payer policy; some allow 100% + 50%)
Example: 67228-50

Timing and Relationship Modifiers

25 - Significant, Separately Identifiable Evaluation and Management Service

When to use: Same-day E/M service that is distinct from the preoperative work for 67228
Example: Patient presents for 6-month diabetic eye exam (99214). During dilated fundus exam, new PDR discovered. Physician counsels patient, discusses risks and benefits, obtains consent, and performs 67228 same day.
Coding: 99214-25, then separately 67228-LT
Documentation: The E/M note must demonstrate that the comprehensive exam and decision-making process were substantial and separate from the procedure decision
Common Denial Reason: If E/M is only preoperative workup for the laser, it should NOT be billed separately

76 - Repeat Procedure, Same Physician

When to use: Rare for 67228, but applicable if same eye requires additional PRP within the 10-day global period of a previous session due to inadequate initial treatment
Example: Day 1 PRP session for right eye. Day 5 patient returns; treatment deemed inadequate; additional session performed to same eye.
Coding: 67228-76-RT
Reimbursement: Typically 100% (some payers reduce to 80-90%)

77 - Repeat Procedure, Different Physician

When to use: Same scenario as 76, but different physician performs the second session
Example: Retina specialist A performs initial PRP; patient follows up with retina specialist B (covering physician) for continuation of treatment within global period
Coding: 67228-77-RT

79 - Unrelated Procedure During Postoperative Period

When to use: Treatment of contralateral (opposite) eye within the 10-day global period of the first eye, OR treatment of first eye when it falls within the global period of prior treatment to second eye
Example:
Right eye 67228-RT on Monday (initiates 10-day global)
Left eye 67228-79-LT on Thursday (Day 4 of right eye global)
Modifier 79 tells payer: “This left eye treatment is unrelated to the right eye global period”
Coding: 67228-79-LT
Reimbursement: Full (100%) because the eyes are distinct anatomical sites
Documentation: Must clearly explain that the second eye is a separate anatomical site with separate treatment indication

51 - Multiple Procedures

When to use: NOT typically used with 67228 in isolation
May apply: If 67228 is billed alongside a different primary procedure on the same date (e.g., 67228 + 99214)
Effect: Secondary procedures are automatically reduced to 50% by most payers
Strategy: Always sequence 67228 as primary (higher-value procedure) if combining with lower-RVU services

Modifiers NOT Permitted

❌ 80, 81, 82 - Assistant Surgeon Modifiers

Status Indicator 0 (not payable); will be denied automatically

❌ 59 - Distinct Procedural Service (Limited Applicability)

Generally not needed for bilateral or contralateral eye treatment (use 50 or 79 instead)
May apply: If 67228 and 67210 billed together on same eye with medical justification

Explorer

67228